Invoice audits focusing on diabetic test strips are common in the PBM world. PAAS National® believes the PBMs and manufacturers have two purposes for requesting these invoice audits. They are checking for inappropriate billing practices (wrong NDC) and inappropriate sources of inventory (unauthorized distributor).
The newest audit PAAS has seen is coming from manufacturers of test strips that offer rebate contracts with pharmacies for Medicare/Medicaid claims. These audits are very similar to other PBM invoice audits, in that they request invoices from authorized distributors for test strips dispensed during the specified timeframe. Since the manufacturer knows the number of rebates paid, they can easily identify potential shortages. Pharmacies without a valid explanation will be required to repay their rebates and will potentially lose their ability to purchase Medicare/Medicaid-only test strips.
Caremark® and Express Scripts® require test strips to be purchased directly from the manufacturer or from authorized distributors only. Manufacturer rebate agreements also have these same requirements. Purchasing diabetic test strips from unauthorized distributors puts your pharmacy at risk of audit recoupments, violation of provider agreements and possible network termination.
- Try to purchase test strips from one approved wholesaler
- Be sure all strip claims are run for the correct NDC and pack size
- Self-audit 5-10 claims at regular intervals for internal review
PAAS Audit Assistance members can view the full article on our eNewsline.
- OIG and GSA Exclusion Checking – Are You Compliant? - September 10, 2021
- Fraud, Waste, & Abuse and HIPAA Compliance Updates for 2021 - April 1, 2021
- Are You Documenting DUR and Submission Clarification Codes? - March 1, 2021